World Pancreatic Cancer Day

United States, Canada, United Kingdom, Australia, New Zealand, Ireland, France, Germany, Italy, Spain, Portugal, Netherlands, Belgium, Switzerland, Austria, Denmark, Sweden, Norway, Finland, Poland, Czech Republic, Greece, Israel, India, Japan, South Korea, Singapore, Malaysia, Philippines, Thailand, China, Brazil, Argentina, Chile, Mexico, Colombia, South Africa

About

World Pancreatic Cancer Day, observed on November 19, brings people around the world together to raise awareness of pancreatic cancer and the challenges faced by those affected by it. The day highlights the importance of learning about risk factors, symptoms, early detection, treatment, and the need for continued medical research.

It is also a time to honor patients, survivors, caregivers, healthcare professionals, and loved ones whose strength and support make a difference throughout the cancer journey. By sharing reliable information, showing compassion, and supporting advocacy and research efforts, communities can help ensure that pancreatic cancer receives greater attention and that no one faces it alone.

History

World Pancreatic Cancer Day is observed on **November 19** to increase public understanding of pancreatic cancer and to draw attention to the need for earlier diagnosis, better treatments, and continued research. The observance emerged from the work of the **World Pancreatic Cancer Coalition (WPCC)**, an international network of pancreatic-cancer organizations that brought together patient advocates, researchers, clinicians, and nonprofit groups. Its development reflected growing concern that pancreatic cancer received less public attention than many other major cancers despite its serious impact and often limited early symptoms.

The campaign became an international observance in the 2010s, with organizations using November—the broader pancreatic-cancer awareness month—to coordinate education and advocacy. World Pancreatic Cancer Day gave these efforts a specific global focus on November 19. Over time, participating groups have expanded the observance beyond basic awareness by promoting information about possible warning signs, risk factors, family history, and the importance of discussing persistent or unusual symptoms with health professionals. The campaign also highlights the challenges created by late diagnosis and the need for improved access to specialized care.

A central feature of the day is the sharing of experiences by patients, survivors, families, caregivers, and medical professionals. Supporters commonly use purple imagery, including the purple pancreatic-cancer ribbon, and may illuminate public buildings, organize educational events, publish personal stories, or conduct fundraising activities. These actions help make a relatively less visible disease part of wider public conversations about cancer prevention, diagnosis, treatment, and survivorship.

Culturally, World Pancreatic Cancer Day has become both a memorial and an advocacy occasion. It honors people who have died from the disease while giving patients and families a platform to call for stronger research and more effective therapies. Its continuing purpose is to transform awareness into action: encouraging informed conversations, supporting those affected, and helping build international momentum for earlier detection and improved outcomes. Source: [National Today, “World Pancreatic Cancer Day”](https://nationaltoday.com/world-pancreatic-cancer-day/).

Timeline

1996
The U.S. Food and Drug Administration approved gemcitabine for pancreatic cancer, establishing a chemotherapy option that became a standard comparator in later pancreatic-cancer trials.
2011
A randomized trial published in The New England Journal of Medicine found that FOLFIRINOX improved survival over gemcitabine in patients with metastatic pancreatic cancer.
2013
The U.S. Food and Drug Administration approved nab-paclitaxel (Abraxane) in combination with gemcitabine for metastatic pancreatic adenocarcinoma.
2019
The U.S. Food and Drug Administration approved olaparib (Lynparza) as maintenance treatment for metastatic pancreatic adenocarcinoma in patients with germline BRCA mutations whose disease had not progressed on platinum chemotherapy.

Upcoming dates

Sources

Same day

Related